The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment

To review the evidence that agents which preferentially affect serotonin (5-HT) attenuate the ability of N-methyl-D-aspartate (NMDA) receptor non-competitive antagonists (NMDA-RA), e.g., phencyclidine (PCP), dizocilpine (MK-801), and ketamine, to stimulate locomotor activity (LA), and to impair novel object recognition (NOR). NMDA-RA-induced increased LA and impairment of NOR are widely used models of the pathophysiology of schizophrenia, the mechanism of action of antipsychotic drugs (APDs), and the identification of novel treatments. Serotonin (5-HT) plays an important role in attenuating these effects of NMDA-RA. Selective 5-HT2A inverse agonists, e.g., M100907 and ACP-103, and atypical APDs, which are more potent 5-HT2A than D-2 antagonists, e.g., clozapine and lurasidone, are more effective than selective D-2 receptor antagonists to attenuate NMDA-RA-induced increased LA. 5-HT2A inverse agonists alone are not effective to improve NMDA-RA-impaired NOR, but augment the effects of atypical, but not typical APDs, to improve NOR. The 5-HT1A receptor partial agonist tandospirone alone and the 5-HT1A agonist effects of atypical APDs may substitute for, or contribute to, the effects of D-2 and 5-HT2A receptor antagonism to reverse the NMDA-RA impairment in NOR. 5-HT6 and 5-HT7 receptor antagonists may also attenuate these NMDA-RA-induced behaviors. 5-HT2C receptor inverse agonist, but not neutral antagonists, block NOR in na < ve rats and the effects of atypical APDs to restore NOR in PCP-treated rats, suggesting the importance of the constitutive activity of 5-HT2C receptors in NOR. Multiple 5-HT receptors contribute to effective treatments to reverse adverse effects of NMDA-RA which model psychosis and cognitive impairment.